Lenalidomide Consolidation Added to Rituximab Maintenance Therapy in Patients Remaining PET Positive After Treatment for Relapsed Follicular Lymphoma: A Phase 2 Australasian Leukaemia & Lymphoma Group NHL26 Study

Judith Trotman^{1

2}, Peter Presgrave³, Duncan P Carradice⁴, Douglas Stuart Lenton^{5

6}, Maher K Gandhi^{7

8}, Tara Cochrane^{9

10}, Xavier Badoux¹¹, Julia Carlson¹², Gloria Nkhoma¹², Belinda Butcher^{11

13}, Armin Nikpour^{2

14}, Michael Fulham^{2

14}, Anna M Johnston^{15

16}

Affiliations

¹ Haematology, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.
² University of Sydney, Camperdown, NSW, Australia.
³ Department of Haematology, Wollongong Hospital, NSW, Australia.
⁴ Department of Haematology and Medical Oncology, Western Health and University of Melbourne, St Albans, VIC, Australia.
⁵ Orange Hospital, NSW, Australia.
⁶ University of Sydney, Orange, NSW, Australia.
⁷ Princess Alexandra Hospital, Brisbane, QLD, Australia.
⁸ Mater Research University of Queensland, Brisbane, QLD, Australia.
⁹ Department of Haematology, Gold Coast University Hospital, Southport, Australia.
¹⁰ Griffith University, Southport, Australia.
¹¹ University of New South Wales, Sydney, NSW, Australia.
¹² Australasian Leukaemia and Lymphoma Group, Richmond, VIC, Australia.
¹³ WriteSource Medical Pty Ltd, Lane Cove, NSW, Australia.
¹⁴ Department of Molecular Imaging, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
¹⁵ Department of Hematology, Royal Hobart Hospital, Hobart, TAS, Australia.
¹⁶ University of Tasmania, Hobart, TAS, Australia.

Judith Trotman et al. Hemasphere. 2023.

. 2023 Feb 21;7(3):e836.

doi: 10.1097/HS9.0000000000000836. eCollection 2023 Mar.

¹ Haematology, Concord Repatriation General Hospital, University of Sydney, Concord, NSW, Australia.
² University of Sydney, Camperdown, NSW, Australia.
³ Department of Haematology, Wollongong Hospital, NSW, Australia.
⁴ Department of Haematology and Medical Oncology, Western Health and University of Melbourne, St Albans, VIC, Australia.
⁵ Orange Hospital, NSW, Australia.
⁶ University of Sydney, Orange, NSW, Australia.
⁷ Princess Alexandra Hospital, Brisbane, QLD, Australia.
⁸ Mater Research University of Queensland, Brisbane, QLD, Australia.
⁹ Department of Haematology, Gold Coast University Hospital, Southport, Australia.
¹⁰ Griffith University, Southport, Australia.
¹¹ University of New South Wales, Sydney, NSW, Australia.
¹² Australasian Leukaemia and Lymphoma Group, Richmond, VIC, Australia.
¹³ WriteSource Medical Pty Ltd, Lane Cove, NSW, Australia.
¹⁴ Department of Molecular Imaging, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.
¹⁵ Department of Hematology, Royal Hobart Hospital, Hobart, TAS, Australia.
¹⁶ University of Tasmania, Hobart, TAS, Australia.

No abstract available

Figures

1. McNamara C, Montoto S, Eyre T, et al. . Update: the investigation and management of follicular lymphoma. Br J Haematol. 2020;191(Suppl 1):307–512. - PubMed
1. Barrington SF, Mikhaeel NG, Kostakoglu L, et al. . Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–3058. - PMC - PubMed
1. Luminari S, Manni M, Galimberti S, et al. . Response-adapted postinduction strategy in patients with advanced-stage follicular lymphoma: the FOLL12 study. J Clin Oncol. 2022;40:729–739. - PubMed
1. Lopez-Girona A, Mendy D, Ito T, et al. . Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:24452326–24452445. - PMC - PubMed
1. Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, et al. . Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol. 2008;140:36–45. - PubMed